BRPI0506705A - composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos - Google Patents

composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos

Info

Publication number
BRPI0506705A
BRPI0506705A BRPI0506705-7A BRPI0506705A BRPI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A BR PI0506705 A BRPI0506705 A BR PI0506705A
Authority
BR
Brazil
Prior art keywords
formula
compounds
pharmaceutical compositions
compound
suffering
Prior art date
Application number
BRPI0506705-7A
Other languages
English (en)
Inventor
Andrew Thurkauf
Dawei Chen
Avinash Phadke
Shouming Li
Milind Deshpande
Original Assignee
Achillion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Achillion Pharmaceuticals Inc filed Critical Achillion Pharmaceuticals Inc
Publication of BRPI0506705A publication Critical patent/BRPI0506705A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

COMPOSTOS DE TIOURéIAS AZABENZOFURAN-SUBSTITUìDAS, COMPOSIçõES FARMACêUTICAS E SEUS USOS A presente invenção fornece compostos de Formula: (1), em que as variáveis AR, A~ 1~, A~ 2~, A~ 3~, A~ 4~, R~ 5~, R~ 6~, R~ 7~, V, W, X e Y são aqui definidos. certos compostos de fórmula (1) aqui descritos possuem atividade antiviral potente. A invenção também fornece compostos de fórmula (1) que são inibidores potentes e/ou seletivos da replicacão do vírus da Hepatite c. A invenção também fornece composições farmacêuticas contendo um ou mais compostos de fórmula (1), ou um sal, solvato ou pró-droga acilada destes compostos, e um ou mais veículos, excipientes ou diluentes farmaceuticamente aceitáveis A invençao ainda compreende métodos de tratamento de pacientes que sofrem de de certas doenças infecciosas pela administração a estes pacientes de uma quantidade de um composto de fórmula (1) eficaz para reduzir sinais ou sintomas da doença. Estas doenças infecciosas incluem infecções virais, particularmente infecções pelo HCV. A invenção inclui particularmente métodos de tratamento de pacientes humanos que sofrem de uma doença infecciosa,mas também engloba métodos de tratamento de outros animais, incluindo animais de criação e animais domesticados companhia, que sofrem de uma doença infecciosa. os métodos de tratamento incluem a administração de um composto de fórmula (1) como um agente ativo único ou a administração de um composto de fórmula (1) em combinação com um ou mais outros agentes terapêuticos.
BRPI0506705-7A 2004-01-06 2005-01-05 composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos BRPI0506705A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53483904P 2004-01-06 2004-01-06
PCT/US2005/000339 WO2005067900A2 (en) 2004-01-06 2005-01-05 Azabenzofuran substituted thioureas as inhibitors of viral replication

Publications (1)

Publication Number Publication Date
BRPI0506705A true BRPI0506705A (pt) 2007-05-02

Family

ID=34794326

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506705-7A BRPI0506705A (pt) 2004-01-06 2005-01-05 composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos

Country Status (19)

Country Link
US (1) US7439374B2 (pt)
EP (1) EP1709047B1 (pt)
JP (1) JP2007517887A (pt)
KR (1) KR20060121289A (pt)
CN (1) CN1946720A (pt)
AP (1) AP2006003659A0 (pt)
AR (1) AR047367A1 (pt)
AT (1) ATE479684T1 (pt)
AU (1) AU2005204369B2 (pt)
BR (1) BRPI0506705A (pt)
CA (1) CA2552002A1 (pt)
DE (1) DE602005023266D1 (pt)
EA (1) EA200601281A1 (pt)
IL (1) IL176486A0 (pt)
NO (1) NO20062928L (pt)
NZ (1) NZ548375A (pt)
OA (1) OA13357A (pt)
TW (1) TW200528459A (pt)
WO (1) WO2005067900A2 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200600492A (en) * 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
AU2007286754A1 (en) * 2006-08-25 2008-02-28 Viropharma Incorporated Identification and characterization of HCV replicon variants with reduced susceptibility to HCV-796, and methods related thereto
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US7985763B2 (en) * 2007-04-10 2011-07-26 National Health Research Institutes Hepatitis C virus inhibitors
TW200848016A (en) * 2007-06-08 2008-12-16 Nat Health Research Institutes Thiourea compound and composition of treating hepatitis C virus infection
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
BRPI0923815A2 (pt) 2008-12-23 2015-07-14 Pharmasset Inc Síntese de nucleosídeos de purina
NZ593649A (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Nucleoside analogs
TWI583692B (zh) 2009-05-20 2017-05-21 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
EP2609923B1 (en) 2010-03-31 2017-05-24 Gilead Pharmasset LLC Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
DK2552930T3 (en) 2010-03-31 2015-12-07 Gilead Pharmasset Llc Crystalline (S) -isopropyl 2 - (((S) - (((2R, 3R, 4R, 5R) -5- (2,4-dioxo-3,4-DIHYDROPYRIMIDIN- 1- (2 H) -yl) - 4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino) propanoate
US8324239B2 (en) 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
ES2659216T5 (es) 2011-09-16 2021-06-09 Gilead Pharmasset Llc Métodos para el tratamiento del VHC
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
EP2860181B1 (en) * 2012-04-10 2019-02-13 Shanghai Yingli Pharmaceutical Co. Ltd. Fused pyrimidine compound, and preparation method, intermediate, composition and uses thereof
PE20151778A1 (es) 2013-01-31 2015-12-16 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales
PT3038601T (pt) 2013-08-27 2020-06-30 Gilead Pharmasset Llc Formulação combinada de dois compostos antivirais
EP3454856A4 (en) 2016-05-10 2019-12-25 C4 Therapeutics, Inc. HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197036A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
EP4108659A1 (en) 2016-06-07 2022-12-28 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
SG11201908820VA (en) 2017-03-23 2019-10-30 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1408198A (en) * 1971-08-23 1975-10-01 Medizinska Akad Antiviral compositions
CN1071930A (zh) * 1991-07-10 1993-05-12 伊莱利利公司 用作治疗艾滋病的人免疫缺陷病毒蛋白酶的抑制剂
GB9504460D0 (en) 1995-03-06 1995-04-26 Bayer Ag N-(3-Benzofuranyl)urea-derivatives
WO1997041846A1 (en) * 1996-05-06 1997-11-13 Eli Lilly And Company Anti-viral compounds
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
NZ539727A (en) * 2002-11-01 2008-01-31 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis C viral infections and associated diseases
NZ540033A (en) * 2002-11-19 2007-05-31 Achillion Pharmaceuticals Inc Substituted aryl thioureas and related compounds; inhibitors of viral replication
EA010017B1 (ru) * 2003-07-10 2008-06-30 Ачиллион Фармасьютикалз, Инк. Замещённые арилтиомочевины, применимые в качестве ингибиторов репликации вирусов

Also Published As

Publication number Publication date
IL176486A0 (en) 2006-10-05
CN1946720A (zh) 2007-04-11
EP1709047B1 (en) 2010-09-01
AP2006003659A0 (en) 2006-06-30
KR20060121289A (ko) 2006-11-28
EA200601281A1 (ru) 2006-12-29
TW200528459A (en) 2005-09-01
EP1709047A2 (en) 2006-10-11
NZ548375A (en) 2010-07-30
JP2007517887A (ja) 2007-07-05
WO2005067900A3 (en) 2005-09-29
OA13357A (en) 2007-04-13
US7439374B2 (en) 2008-10-21
NO20062928L (no) 2006-08-03
DE602005023266D1 (de) 2010-10-14
AU2005204369B2 (en) 2010-06-10
AU2005204369A1 (en) 2005-07-28
US20050228013A1 (en) 2005-10-13
AR047367A1 (es) 2006-01-18
ATE479684T1 (de) 2010-09-15
WO2005067900A2 (en) 2005-07-28
CA2552002A1 (en) 2005-07-28

Similar Documents

Publication Publication Date Title
BRPI0506705A (pt) composto de tiouréias azabenzofuran-substituìdas, composições farmacêuticas e seus usos
BR0316397A (pt) Tiouréias aril substituìdas e compostos relacionados como inibidores de replicação viral
TW200600492A (en) Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
UA92746C2 (en) Thiazole compounds and methods of use
WO2005095345A3 (en) Heteroaryl guanidines as inhibitors of viral replication
Geier et al. A review of Thimerosal (Merthiolate) and its ethylmercury breakdown product: specific historical considerations regarding safety and effectiveness
KR101706624B1 (ko) 고병원성 감염성 질환의 예방 및 치료제
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
ES2187575T3 (es) Hexapeptidos ciclicos dotados de actividad antibiotica.
BR0309670A (pt) Compostos derivados dicetohidrazina e drogas contendo os compostos como o ingrediente ativo
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
ES2570401T3 (es) Métodos de tratamiento usando dosis únicas de oritavancina
BRPI0407140A (pt) Droga terapêutica para vìrus
RU2738719C1 (ru) Средство для лечения коронавирусных, ретровирусных инфекций и гепатита с
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
EA202100186A2 (ru) Вакцина и способ защиты от коронавирусной инфекции
ES2207166T3 (es) Composicion fungicida que comprende una benzoilfenilurea.
RU2420309C2 (ru) Препарат против бешенства
RU2009112724A (ru) Циклические сульфоны в качестве митохондриальных натрий-кальциевых обменников
Waghchaure et al. A REVIEW ON: COVID-19, THE STEP TOWARDS PREVENTION, TREATMENT
RU2663324C1 (ru) Способ лечения кроликов при миксоматозе
KR20060054190A (ko) 코로나 바이러스를 불활성화시키는 제제
JP2018518453A (ja) 糖尿病創傷治療用イソキノリン誘導体の新規使用
US20060057133A1 (en) Topical pathogenic-tissue-destroying liquid
RU2188001C2 (ru) Способ лечения миксоматоза и вирусной геморрагической болезни кроликов

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.